Genetic risk prediction for hereditary ovarian cancer
A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration
Peking University Third Hospital · NCT06564428
This study is trying to create a way to predict the risk of ovarian cancer in families with a history of the disease to help guide prevention efforts for those at high risk.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Peking University Third Hospital (other) |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06564428 on ClinicalTrials.gov |
What this trial studies
This project aims to establish a multicenter cohort of hereditary ovarian cancer patients in China to analyze their clinicopathologic features and develop a risk prediction model. By following up on clinical and pathological data, genetic test results, and family histories, the study seeks to quantify cancer risk in first-degree relatives of mutation carriers. Additionally, it aims to identify novel tumor-causing mutations and predisposing genes through gene sequencing in families with hereditary tumors. The ultimate goal is to guide preventive interventions for high-risk populations.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with epithelial ovarian cancer who have germ line pathogenic or suspected pathogenic mutations.
Not a fit: Patients with non-epithelial ovarian cancer or those who have not undergone genetic testing may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly improve risk assessment and management strategies for individuals at high risk of hereditary ovarian cancer.
How similar studies have performed: Other studies have shown success in developing genetic risk prediction models for various cancers, suggesting potential for this approach in ovarian cancer as well.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Epithelial ovarian cancer * ≥18 years * The pathological diagnosis was clear * The genetic test showed germ line pathogenic/suspected pathogenic mutations (for mutation interpretation, refer to the American ACMG Classification Standards and Guidelines for Genetic Variation) Exclusion Criteria: * Non-epithelial ovarian cancer was confirmed by pathology * No genetic test has been performed
Where this trial is running
Beijing, Beijing Municipality
- Peking University Third Hospital — Beijing, Beijing Municipality, China (RECRUITING)
Study contacts
- Principal investigator: Hongyan Guo, Doctor — Peking University Third Hospital
- Study coordinator: Yuan Li, Doctor
- Email: yuanli@bimu.edu.cn
- Phone: 18610689868
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Ovarian Neoplasms